Abstract
Naxitamab (DANYELZA®, naxitamab-gqgk) is a humanised (IgG1) anti-GD2 (hu3F8) monoclonal antibody was developed by the Memorial Sloan Kettering Cancer Center (with commercial rights licenced to Y-mAbs therapeutics Inc.) for the treatment of neuroblastoma, osteosarcoma and other GD2-positive cancers. Naxitamab was recently granted accelerated approval by the US FDA for marketing as treatment (in combination with granulocyte-macrophage colony-stimulating factor) for paediatric patients at least one year of age and adult patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow demonstrating a partial response, minor response, or stable disease to prior therapy. This article summarizes the milestones in the development of naxitamab leading to this first approval.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Cheung NK, Guo H, Hu J, et al. Humanizing murine IgG3 anti-GD2 antibody m3F8 substantially improves antibody-dependent cell-mediated cytotoxicity while retaining targeting in vivo. Oncoimmunology. 2012;1(4):477–86.
US Food & Drug Administration. FDA grants accelerated approval to naxitamab for high-risk neuroblastoma in bone or bone marrow [media release]. 27 Nov 2020. https://www.fda.gov/drugs/drug-approvals-and-databases/fda-grants-accelerated-approval-naxitamab-high-risk-neuroblastoma-bone-or-bone-marrow.
Y-mAbs Therapeutics Inc. DANYELZA® (naxitamab-gqgk) injection, for intravenous use): US prescribing information. 2020. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761171lbl.pdf. Accessed 27 Nov 2020.
Therapeutics Ym. Y-mAbs Therapeutics, Inc. joins forces with Cancer Center to break new ground on immunotherapy [media release]. 14 Oct 2015. http://www.ymabs.com.
Therapeutics Ym. Y-mAbs Therapeutics, Inc. enters into development and manufacturing agreement for antibody compound with Patheon Biologics [media release]. 2 Dec 2015. http://www.ymabs.com.
Kushner BH, Cheung IY, Modak S, et al. Humanized 3F8 Anti-GD2 monoclonal antibody dosing with granulocyte-macrophage colony-stimulating factor in patients with resistant neuroblastoma: a phase 1 clinical trial. JAMA Oncol. 2018;4(12):1729–35.
Mora J, Chan G, Morgenstern DA, et al. Efficacy and updated safety results from pivotal phase II trial 201 of naxitamab (Hu3F8): a humanized GD2-targeted immunotherapy for the treatment of refractory/relapsed (R/R) high-risk (HR) neuroblastoma (NB) [abstract no. 75P]. Ann Oncol. 2020;31(Suppl 7):S1441–51.
Mora J, Castaneda A, Flores M, et al. Naxitamab-based chemoimmunotherapy for resistant high-risk neuroblastoma: preliminary results of Hits treatment [abstract no. 434]. Pediatric Blood Cancer. 2020;67(Suppl 4):S32.
Kushner B, Modak S, Basu E, et al. High-dose naxitamab (humanized-3F8) plus stepped-up dosing of granulocyte-macrophage colony-stimulating factor (GM-CSF) for resistant osteomedullary neuroblastoma: major responses and outpatient treatment in a phase II trial [abstract no. 863]. Pediatric Blood Cancer. 2020;67(Suppl 4):S32.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Funding
The preparation of this review was not supported by any external funding.
Authorship and Conflict of interest
During the peer review process the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from any comments received were made by the authors on the basis of scientific completeness and accuracy. A. Markham is a contracted employee of Adis International Ltd/Springer Nature, and declares no relevant conflicts of interest. All authors contributed to the review and are responsible for the article content.
Ethics approval, Consent to participate, Consent to publish, Availability of data and material, Code availability
Not applicable.
Additional information
This profile has been extracted and modified from the AdisInsight database. AdisInsight tracks drug development worldwide through the entire development process, from discovery, through pre-clinical and clinical studies to market launch and beyond.
Rights and permissions
About this article
Cite this article
Markham, A. Naxitamab: First Approval. Drugs 81, 291–296 (2021). https://doi.org/10.1007/s40265-021-01467-4
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40265-021-01467-4